Four rounds, one day, four different stories
On November 17, four companies announced large rounds, and the stage names on them barely line up with the dollars. A robotics company called its raise a Series A at $500 million. A financial-services AI platform closed a $250 million Series B. A neurotechnology company took a $400 million Series D. A drug-discovery lab raised a $5 billion Series C.
For founders planning a raise, the useful lesson is not the size. It is how little a stage label now communicates, and how much the surrounding disclosure shapes what investors, employees and future lenders believe about the company.
Here is what each company actually said, and what it chose to leave out.
Genesis AI: a $500 million "Series A"
Genesis AI announced a $500 million Series A co-led by Khosla Ventures, Premji Invest and Eclipse, according to TechCrunch. The company's prior round was a $105 million seed announced in July 2025, so the Series A arrived roughly 16 months later and was nearly five times the size of the seed.
The operating picture is early. TechCrunch reports the company has built 30 to 40 of its Eno humanoid robots, is piloting them with "a handful of undisclosed customers," and has not disclosed revenue. It also reports that the robot's dexterous hands last only a few weeks of regular work before replacement. The company has chosen a U.S. mass-manufacturing contractor to begin work next year.
Valuation is where the coverage splits. The Next Web reports a $3.5 billion valuation without specifying pre- or post-money. TechCrunch says the valuation was not disclosed. We are not building on the $3.5 billion figure for that reason, and the disagreement is itself a point: when a company does not state the basis for a valuation, every outlet fills the gap differently.
Model ML: growth multiples need a base
Model ML, which sells AI agents to bankers, consultants and investors that run inside a firm's own systems, announced a $250 million Series B at a $1.5 billion valuation. General Atlantic and QED Investors led. The company says it raised a $75 million Series A led by FT Partners in November 2025, and that total funding is now $350 million.
The company's own metrics are annual recurring revenue up 12x year over year and daily active users up 26x in the third quarter of 2026. Those are company-reported figures, and the announcement does not give the dollar base. A 12x multiple on a small number and a 12x multiple on a large one lead to very different diligence conversations.
The pattern is common in announcements: growth is stated as a multiple, scale is left unstated. Founders should expect diligence teams to ask for the denominator on day one, and should have the monthly series ready in the data room rather than wait to be asked.
Science: the use of proceeds is the pitch
Science Corporation announced a $400 million Series D with participation from Khosla Ventures, Tenet Healthcare, Y Combinator and others. The company says it has raised more than $900 million since its 2021 founding, including this round.
It did not state a valuation. One tracker's roundup attributes a $3.5 billion figure to a TechCrunch report citing a person familiar with the deal. We treat that as unconfirmed, because it is not company-disclosed and rests on an unnamed source.
What Science did say is specific. The proceeds go to expanding availability of its PRIMA retinal implant in Europe, preparing a U.S. launch through the FDA's Humanitarian Device Exemption pathway, building research and manufacturing capacity, and further investment in a biohybrid neural interface program. A use-of-proceeds list tied to regulatory milestones gives later investors something to hold management to, which is worth more at the Series D stage than a headline number.
Isomorphic Labs: the quiet signal is the cadence
Isomorphic Labs raised $5 billion in a Series C co-led by Greenoaks and Sequoia Capital, with Andreessen Horowitz, Alphabet and existing investors participating. pharmaphorum describes the previous round, a $2.1 billion raise, as closing only a few months earlier. It says the money funds simulation models, drug candidate pipelines and bioengineering infrastructure.
The company did not announce a valuation, and the figure of about $50 billion that circulates is an outside estimate, so it is not used here.
The point for smaller companies is the cadence. Two rounds within a few months mean the earlier investors were being priced against a new set of milestones almost immediately. Founders who raise a large round and expect a long quiet period before the next one should read this as an exception, not a template.
What founders can take from this
Define your stage by what is true, not what is conventional. Investors read Series A, B and C as shorthand for traction and risk. When the label and the numbers diverge, as with a $500 million Series A, the diligence questions simply move to other places: unit economics, manufacturing readiness, regulatory path. Be ready for them.
State the basis of any valuation. If a number is post-money, say so in the announcement and in the term sheet language you share with press. The Genesis coverage shows what happens when you do not: one outlet publishes a figure, another says none was disclosed.
Give the denominator. If you cite growth as a multiple, have the underlying dollar or user figures ready. Sophisticated investors will rebuild the base from your data room anyway, and being forthcoming first shortens the conversation.
Tie proceeds to dated milestones. Science's list, with a European rollout, a U.S. pathway and manufacturing capacity, is the kind of specificity a lead investor can underwrite and a later investor can check.
Expect your announcement to be reread by lenders and hires. The round post is the first document venture lenders, recruiters and prospective customers read, and it will be quoted back to you.
What to watch next
Watch whether Genesis AI discloses the pre- or post-money basis of its valuation, and whether it names customers beyond the undisclosed pilots. Watch whether Model ML publishes a revenue base alongside its growth multiples. And watch how Science sequences its Humanitarian Device Exemption filing, because that regulatory timeline is what its Series D is financing.
None of this is advice on any investment. It is a reminder that in a market where stage names stretch, the details you disclose are what carry credibility.
Sources
- TechCrunch: Genesis AI raises $500 million to deploy electric glove-wearing robots
- The Next Web: Genesis AI raises $500m at a $3.5bn valuation to put Eno robots to work
- Model ML: raises $250 million at $1.5 billion valuation 18 months after launching from stealth
- Science Corporation: Series D announcement
- pharmaphorum: Isomorphic Labs raises $5bn in massive third round
- Tech Startups: Startup Funding News Today, November 18, 2026